Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2012
06/28/2012WO2012088033A2 Novel pharmaceutical composition
06/28/2012WO2012088015A2 Substituted hydroxamic acids and uses thereof
06/28/2012WO2012087962A2 Anti-mesothelin antibodies and immunoconjugates
06/28/2012WO2012087943A2 Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
06/28/2012WO2012087889A2 Dna methylation inhibitors
06/28/2012WO2012087881A1 N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
06/28/2012WO2012087242A1 Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
06/28/2012WO2012087017A2 Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof and method for preparing same
06/28/2012WO2012086964A2 Amphiphilic cyclic phosphazene trimer, hydrophobic pharmaceutical formulation micellized by amphiphilic cyclic phosphazene trimer, and preparation methods thereof
06/28/2012WO2012086857A1 Combination body for photodynamic diagnosis or therapy and a production method therefor
06/28/2012WO2012086683A1 Metal-salen complex compound and production method for same
06/28/2012WO2012086184A1 Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient
06/28/2012WO2012086114A1 Macrolide compound having anticancer effect
06/28/2012WO2012085815A1 Bi-heteroaryl compounds as vps34 inhibitors
06/28/2012WO2012085793A1 Use of pegylated recombinant human arginase for treatment of leukemia
06/28/2012WO2012085789A1 Agents for clearing biomolecules from circulation
06/28/2012WO2012085501A1 8 - sulfo - imidazotetrazin- 4 - one compounds and their use as anticancer drug
06/28/2012WO2012085244A1 Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
06/28/2012WO2012085222A1 Novel phenazine derivatives and their use
06/28/2012WO2012085189A1 Ingenol-3-acylates i
06/28/2012WO2012085171A2 Pharmaceutical compositions of pyridinium and quinolinium derivatives
06/28/2012WO2012085132A1 Antibodies against human cd39 and use thereof
06/28/2012WO2012085127A1 New triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
06/28/2012WO2012085126A1 Oxindolopyrimidine as igf1r receptor inhibitors
06/28/2012WO2012085111A1 Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
06/28/2012WO2012084993A2 Biologically active oligonucleotides capable of modulating the immune system i
06/28/2012WO2012084991A1 Biologically active oligonucleotides capable of modulating the immune system ii
06/28/2012WO2012084683A1 Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
06/28/2012WO2012084602A1 Aryl triazole compounds with antitumoural activity
06/28/2012WO2012084267A1 Derivatives of englerin for the treatment of cancer
06/28/2012WO2012083954A1 3-acyl-ingenols ii
06/28/2012WO2012083953A1 Ingenol-3-acylates iii and ingenol-3-carbamates
06/28/2012WO2012083866A1 Quinoline derivatives as anti-cancer agents
06/28/2012WO2012083592A1 Artificial oil body carrier used for targeted breast cancer therapy and preparation method and application of the same
06/28/2012WO2012061390A3 Therapeutic compositions and methods
06/28/2012WO2012058768A8 Stable heterodimeric antibody design with mutations in the fc domain
06/28/2012WO2012054717A3 Detecting and treating solid tumors through selective disruption of tumor vasculature
06/28/2012WO2012051204A3 Antimicrobial formulations that aid in wound healing
06/28/2012WO2012048259A3 Substituted pyridazine carboxamide compounds
06/28/2012WO2012048258A3 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
06/28/2012WO2012047339A9 Anti-cxcr4 as a sensitizer to cancer therapeutics
06/28/2012WO2012037410A3 Estrogen receptor modulators and uses thereof
06/28/2012WO2012036412A9 Peptide having a vascularization-suppressing activity and a use therefor
06/28/2012WO2012031137A3 Vesicular stomatitis viruses
06/28/2012WO2012030160A3 Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
06/28/2012WO2012024519A4 Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
06/28/2012WO2012021016A9 Lactobacillus strain having anti-cancer activity and anti-cancer activity composition including same as active ingredient
06/28/2012WO2012013331A3 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
06/28/2012WO2011162558A3 Recombinant vector for suppressing proliferation of human papillomavirus cell including adenylate cyclase activating polypeptide 1 (pituitary) gene and pharmaceutical composition for treating human papillomavirus
06/28/2012WO2011154505A3 Complex product comprising a cellular carrier and a cytoxic chemotherapeutic drug
06/28/2012US20120165522 Camptothecin derivatives
06/28/2012US20120165406 Bis-trifluoromethyl honokiol analogs and their use in treating cancers
06/28/2012US20120165403 Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor
06/28/2012US20120165398 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
06/28/2012US20120165397 Chemical modification of short small hairpin rnas for inhibition of gene expression
06/28/2012US20120165395 Bruton's Tyrosine Kinase As Anti-Cancer Drug Target
06/28/2012US20120165393 Peptide-Based In Vivo siRNA Delivery System
06/28/2012US20120165390 Compositions and Methods for Therapy and Diagnosis of Cancer
06/28/2012US20120165384 Inhibition of histone acetyltransferases by ctk7a and methods thereof
06/28/2012US20120165382 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
06/28/2012US20120165378 Thiophene-carboxamides useful as inhibitors of protein kinases
06/28/2012US20120165372 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
06/28/2012US20120165371 Spiro substituted compounds as angiogenesis inhibitors
06/28/2012US20120165370 Quinoline derivatives as anti-cancer agents
06/28/2012US20120165368 Pyrazolopyridine kinase inhibitors
06/28/2012US20120165367 Azaindazoles useful as inhibitors of kinases
06/28/2012US20120165365 Compositions and Methods for Treating Cancer
06/28/2012US20120165362 Androgen receptor modulator compounds and methods
06/28/2012US20120165355 Methods and compositions for treating cancers
06/28/2012US20120165352 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof
06/28/2012US20120165351 Quinazoline derivatives
06/28/2012US20120165340 Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
06/28/2012US20120165335 Cdk inhibitors
06/28/2012US20120165334 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors
06/28/2012US20120165333 C-met protein kinase inhibitors
06/28/2012US20120165330 Quinazolinone and related analogs as sirtuin modulators
06/28/2012US20120165329 Compounds and methods for kinase modulation, and indications therefor
06/28/2012US20120165328 Inhibitors of b lymphocyte kinase
06/28/2012US20120165326 Derivatives of 6-(6-substituted-triazolopyridazine-sulfanyl) 5-fluoro benzothiazoles and 5-fluoro benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
06/28/2012US20120165324 Therapeutic compositions and related methods of use
06/28/2012US20120165322 Rho kinase inhibitors
06/28/2012US20120165321 Quinoline derivatives as pi3 kinase inhibitors
06/28/2012US20120165319 Inhibitors of interleukin-1 beta converting enzyme
06/28/2012US20120165318 Heterocyclic compounds for the inhibition of pask
06/28/2012US20120165317 8-substituted benzoazepines as toll-like receptor modulators
06/28/2012US20120165316 Substituted hydroxamic acids and uses thereof
06/28/2012US20120165314 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
06/28/2012US20120165313 Pyrimidine compounds, compositions and methods of use
06/28/2012US20120165311 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
06/28/2012US20120165310 Ether derivatives of bicyclic heteroaryls
06/28/2012US20120165309 Hetero ring derivative
06/28/2012US20120165308 Use of parthenolide derivatives as antileukemic and cytotoxic agents
06/28/2012US20120165307 Azaindoles useful as inhibitors of janus kinases
06/28/2012US20120165306 Pyrazinylpyridines useful for the treatment of proliferative diseases
06/28/2012US20120165305 Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
06/28/2012US20120165303 Triazolyl phenyl benzenesulfonamides
06/28/2012US20120165300 Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
06/28/2012US20120165298 Sulfonamide compounds
06/28/2012US20120165296 Bisphosphonate-prodrugs
06/28/2012US20120165292 METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE
1 ... 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 ... 2211